InsidersTradesSigma
Follow the Integra Lifesciences Holdings CORP stock price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Integra Lifesciences Holdings CORP has logged 167 reports. Market capitalisation: €1.3bn. The latest transaction was filed on 4 September 2026 (Retenue fiscale). Among the most active insiders: Mosebrook Jeffrey. The full history is accessible without an account.
167
Insider Decl.
n/a
Thresholds
€3m
5 ops.
Buy Volume
€23m
22 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Integra Lifesciences Holdings CORP Hold (neutral), based on 9 analysts. Average price target: US$19.56.
29Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,080 of 29,062 companies
25.7
score / 100
Value17
Quality34
FCF yld-3.4%
Earn yld-39%
EV/EBITDA·
ROE-0.7%
Gross mgn51%
Net mgn-32%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 September 2026
Declarations167 total
1,455 shares@ US$16.62Common StockSEC:0001990905-26-000004:0
5,226 shares@ US$18.050.0070% mcap44.0% of flowCommon StockSEC:0001983748-26-000003:0
937 shares@ US$17.890.0013% mcap6.6% of flowCommon StockSEC:0001719686-26-000003:0
1,216 shares0Common StockSEC:0001949782-26-000001:0
5,420 shares@ US$9.6140.8% of flowCommon StockSEC:0001990905-26-000002:0
8,089 shares@ US$9.6123.6% of flowCommon StockSEC:0001983748-26-000001:0
2,354 shares@ US$9.552.1% of flowCommon StockSEC:0001814943-26-000001:0
341 shares@ US$9.551.2% of flowCommon StockSEC:0001719686-26-000001:0
687 shares@ US$9.551.5% of flowCommon StockSEC:0001563606-26-000001:0
848 shares0Common StockSEC:0001743760-26-000002:0
9,000 shares@ US$11.35100.0% of flowCommon StockSEC:0001251036-25-000006:0
Canonical exit: 3 Feb 2026 (T+90)
11,965 shares0Common StockSEC:0001949782-25-000003:0
2,139 shares@ US$15.1342.4% of flowCommon StockSEC:0000917520-25-000083:0
200,000 shares@ US$13.6262.8% of flowCommon StockSEC:0000917520-25-000078:0
2,561 shares@ US$13.4913.6% of flowCommon StockSEC:0000917520-25-000063:0
3,345 shares@ US$13.4916.7% of flowCommon StockSEC:0000917520-25-000062:0
937 shares@ US$13.255.5% of flowCommon StockSEC:0000917520-25-000061:0
19,592 shares0Common StockSEC:0000917520-25-000045:0
6,939 shares0Common StockSEC:0000917520-25-000046:0
6,939 shares0Common StockSEC:0000917520-25-000044:0
19,592 shares0Common StockSEC:0000917520-25-000048:0
6,939 shares0Common StockSEC:0000917520-25-000043:0
19,592 shares0Common StockSEC:0000917520-25-000047:0
392 shares@ US$12.2580.2% of flowCommon StockSEC:0000917520-25-000049:0
1,655 shares@ US$23.9534.9% of flowCommon StockSEC:0000917520-25-000028:0
25 of 167 declarations
关于 Integra Lifesciences Holdings CORP
Integra LifeSciences Holdings Corp.（股票代码：IART）是一家总部位于新泽西州普林斯顿的美国医疗技术公司，在美国纳斯达克市场上市。该公司成立于 1989 年，最初围绕一种旨在修复和再生组织的工程胶原技术平台构建，此后已发展成为一家多元化的医疗技术企业，服务于外科、神经科、耳鼻喉科 (ENT) 和再生护理应用。其客户群主要是医院、外科医生和专科护理提供者。([sec.gov](https://www.sec.gov/Archives/edgar/data/917520/000091752025000017/R9.htm?utm_source=openai)) Integra 的商业模式以一系列互补产品和解决方案为中心，这些产品和解决方案应用于手术室和邻近的临床环境。该公司销售用于神经外科、普通外科、组织重建、伤口护理和耳鼻喉科手术的设备和耗材。这种组合使 Integra 能够接触多个终端市场，同时使其战略专注于专业化、高价值的医疗技术，而非商品化设备。实际上，这意味着该公司在临床效用、外科医生关系、产品创新和监管执行方面展开竞争，所有这些在医疗设备行业都至关重要。([sec.gov](https://www.sec.gov/Archives/edgar/data/0000917520/000091752025000017/iart-20241231.htm?utm_source=openai)) 从竞争角度来看，Integra 属于专业医疗技术供应商，而非最大的多元化医疗保健集团。其差异化在于适应症特定专业知识的深度、广泛的外科产品组合以及将收购和制造能力整合到其产品平台中的能力。最近的披露显示，该公司继续专注于产品组合优化和运营改进，包括计划从马萨诸塞州布伦特里的一家最先进的制造工厂重新推出 SurgiMend 和 PriMatrix，预计在 2026 年上半年实现运营准备就绪。([sec.gov](https://www.sec.gov/Archives/edgar/data/917520/000091752024000092/ex991-q22024earningsrelease.htm?utm_source=openai)) 最近的公司更新还强调了持续的执行工作和商业势头。在 2025 年 2 月发布的 2024 年第四季度和全年业绩中，Integra 报告了季度收入增长，并描述了 Acclarent ENT 收购的早期整合进展。对于股票投资者而言，关键的分析点是执行风险、制造质量、产品重新发布时间以及公司将其专业产品组合转化为美国和国际市场可持续有机增长的能力。作为在美国纳斯达克上市的发行人，Integra 仍然是外科和再生医疗设备领域值得关注的公司。([sec.gov](https://www.sec.gov/Archives/edgar/data/0000917520/000091752025000014/ex991q42024earnings.htm?utm_source=openai))
